

February 26, 2013

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

Ladies and Gentlemen:

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Jazz Pharmaceuticals Public Limited Company has made disclosure pursuant to those provisions in its Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the Securities and Exchange Commission on February 26, 2013.

Respectfully submitted,

Jazz Pharmaceuticals Public Limited Company

/s/ Suzanne Sawochka Hooper

Suzanne Sawochka Hooper

Executive Vice President and General Counsel

Fourth Floor, Connaught House,
One Burlington Road, Dublin 4, Ireland
p 353.1.634.7800 f 353.1.634.7850

Jazz Pharmaceuticals plc. Registered in Ireland (company number 399192). Registered Office: Fourth Floor, Connaught House, One Burlington Road, Dublin 4, Ireland. Directors: Bruce C. Cozadd - Chairman (USA), Paul L. Berns (USA), Patrick G. Enright (USA), James C. Mermiazee (USA), Seamus Mulligan, Kenneth W. O'Keefe (USA), Catherine A. Sohn (USA), Rick E. Winningham (USA)